Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

Next Previous
Trial Profile

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Modakafusp alfa (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms iinnovate-2
  • Sponsors Takeda; Takeda Development Center Americas

Most Recent Events

  • 06 Aug 2025 Protocol has been amended , to include new arm (Experimental: Group 3 (RRMM Triplets) Arm D: Modakafusp alfa + Daratumumab + Pomalidomide) , changed from 6 to 7.
  • 06 Aug 2025 Status changed to discontinued.
  • 19 Jul 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top